The FDA has issued a complete response letter to AstraZeneca regarding its application for subcutaneous administration of Saphnelo (anifrolumab) in adults with systemic lupus erythematosus. The ...
AstraZeneca said the U.S. Food and Drug Administration rejected an initial submission for its Saphnelo lupus drug in injection form, and vowed to work with the regulator to move forward with an ...
BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results